文献速递银屑病与炎症性皮肤病

银屑病患者工作生产力和活动受损问卷(WPAI)的最小临床重要差值(MCID)

Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2018-06-26

基于UNCOVER-1/-2/-3三项3期试验中3126例银屑病患者数据,采用锚定法(以PASI 75%/90%/100%改善、sPGA 0/0,1及DLQI MCID为锚)辅以分布法,并经ROC验证,估计WPAI-PsO工作生产力损失和活动受损两个维度的MCID均为20%。

要点

  • WPAI-PsO工作生产力损失维度的MCID估计为20%。
  • WPAI-PsO活动受损维度的MCID估计为20%。
  • 锚定法结果获分布法支持,ROC分析提示20%改善最能代表临床有意义获益。

核心结论

  • 银屑病患者WPAI-PsO工作生产力损失和活动受损两个维度的MCID均估计为20%。

研究设计与样本

  • 基于UNCOVER-1/-2/-3三项3期试验中随机分配至安慰剂组和两个依奇珠单抗治疗组(每2周或每4周给药)的银屑病患者数据,采用治疗不可知分析。
  • WPAI-PsO在UNCOVER-1/-2/-3的基线和第12周给药,在UNCOVER-1/-2的第24、36、52和60周给药。
  • 第12周前的MCID采用锚定法辅以分布法推导,锚包括PASI 75%/90%/100%改善、sPGA[0]和sPGA[0,1]以及DLQI MCID。
  • MCID通过ROC和分布法进行三角验证。

主要发现

  • 分析纳入3126例患者(安慰剂组792例,依奇珠单抗组2334例)。
  • 所有锚均显示有效。
  • 在已验证锚中达到临床有意义改善的患者与未达到者之间,WPAI-PsO各维度差异显著(所有P值<0.001)。
  • ROC分析提示工作生产力损失或活动受损成分改善20%最能代表达到已验证锚临床有意义改善的获益。
  • 分布法支持锚定法结果。

关键数值与推荐

  • WPAI-PsO工作生产力损失维度MCID估计为20%。
  • WPAI-PsO活动受损维度MCID估计为20%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical meaningfulness of improvements in the Work Productivity and Activity Impairment Questionnaire for Psoriasis (WPAI-PsO) reported by patients with psoriasis in response to treatment is unknown due to the lack of any publications that report minimal clinically importance differences (MCID) for WPAI-PsO outcomes. OBJECTIVE: To determine the MCIDs for the work productivity loss and activity impairment domains of the Work Productivity and Activity Impairment Questionnaire for Psoriasis (WPAI-PsO) using results from three Phase 3 trials of ixekizumab. METHODS: MCIDs for WPAI-PsO domains were derived using treatment agnostic data from patients participating in UNCOVER-1/-2/-3. The analysis included patients randomized to placebo and two ixekizumab treatment groups (ixekizumab either every 2 weeks or 4 weeks) from the trials. WPAI-PsO was administered at baseline and Week 12 for UNCOVER-1/-2/-3 and at Weeks 24, 36, 52 and 60 in UNCOVER-1/-2. MCIDs for the WPAI-PsO domains through Week 12 were derived using an anchor-based method supplemented with the distribution-based method. Anchors included 75%/90%/100% improvement in Psoriasis Area and Severity Index, Static Physicians Global Assessment (sPGA[0] and sPGA[0,1]) and Dermatology Life Quality Index MCID). MCIDs were triangulated using receiver operating characteristics (ROC) and distribution-based methods. RESULTS: The analyses included 3126 patients (Placebo: 792, Ixekizumab: 2334). All anchors were shown to be valid. Significant differences in the domains of WPAI-PsO were observed between patients achieving clinically meaningful improvement in the validated anchors (all P-values < 0.001). ROC analyses suggested a 20% improvement in the work productivity loss or activity impairment components best represented the benefit of meeting a clinical meaningful improvement in the validated anchors. The distribution-based method supported the results of the anchor-based method. CONCLUSION: The MCIDs for both the work productivity loss and the activity impairment domains of WPAI-PsO were estimated to be 20% in patients with PsO.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Wu JJ, Lin C, Sun L, et al. Minimal clinically important difference (MCID) for work productivity and activity impairment (WPAI) questionnaire in psoriasis patients. J Eur Acad Dermatol Venereol. 2018. PMID: 29846976. doi:10.1111/jdv.15098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。